Synthesis of Taxifolin-Loaded Polydopamine for Chemo-Photothermal-Synergistic Therapy of Ovarian Cancer
Chemotherapy is a well-established method for treating cancer, but it has limited effectiveness due to its high dosage and harmful side effects. To address this issue, researchers have explored the use of photothermal agent nanoparticles as carriers for precise drug release in vivo. In this study, three different sizes of polydopamine nanoparticles (PDA-1, PDA-2, and PDA-3) were synthesized and evaluated. PDA-2 was selected for its optimal size, encapsulation rate, and drug loading rate. The release of the drug from PDA-2TAX was tested at different pH and NIR laser irradiation levels. The results showed that PDA-2@TAX released more readily in an acidic environment and exhibited a high photothermal conversion efficiency when exposed to an 808 nm laser. In vitro experiments on ovarian cancer cells demonstrated that PDA-2@TAX effectively inhibited cell proliferation, highlighting its potential for synergistic chemotherapy-photothermal treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 29(2024), 5 vom: 28. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80168379AG |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 15.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules29051042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369642708 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369642708 | ||
| 003 | DE-627 | ||
| 005 | 20240315233852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules29051042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369642708 | ||
| 035 | |a (NLM)38474556 | ||
| 035 | |a (PII)1042 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis of Taxifolin-Loaded Polydopamine for Chemo-Photothermal-Synergistic Therapy of Ovarian Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chemotherapy is a well-established method for treating cancer, but it has limited effectiveness due to its high dosage and harmful side effects. To address this issue, researchers have explored the use of photothermal agent nanoparticles as carriers for precise drug release in vivo. In this study, three different sizes of polydopamine nanoparticles (PDA-1, PDA-2, and PDA-3) were synthesized and evaluated. PDA-2 was selected for its optimal size, encapsulation rate, and drug loading rate. The release of the drug from PDA-2TAX was tested at different pH and NIR laser irradiation levels. The results showed that PDA-2@TAX released more readily in an acidic environment and exhibited a high photothermal conversion efficiency when exposed to an 808 nm laser. In vitro experiments on ovarian cancer cells demonstrated that PDA-2@TAX effectively inhibited cell proliferation, highlighting its potential for synergistic chemotherapy-photothermal treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PDA | |
| 650 | 4 | |a TAX | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a photothermal agent nanoparticles | |
| 650 | 7 | |a polydopamine |2 NLM | |
| 650 | 7 | |a taxifolin |2 NLM | |
| 650 | 7 | |a 9SOB9E3987 |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Quercetin |2 NLM | |
| 650 | 7 | |a 9IKM0I5T1E |2 NLM | |
| 700 | 1 | |a Liu, Xinglong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Chuanbo |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Qiteng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wencong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 29(2024), 5 vom: 28. Feb. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:5 |g day:28 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules29051042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 5 |b 28 |c 02 | ||